Hinova Pharmaceuticals (SH:688302) Xin Lang Cai Jing·2025-09-23 06:06Group 1 - Hecion Pharmaceutical experienced a decline of 5.05% on September 23, with a stock price of 51.13 yuan per share and a total market capitalization of 5.063 billion yuan [1] - The company, established on February 5, 2013, and listed on April 12, 2022, focuses on developing Best-in-class and First-in-class drugs using deuterated technology and PROTAC targeted protein degradation [1] - The main revenue composition of Hecion Pharmaceutical is 99.25% from pharmaceuticals and 0.75% from the sale of materials and research intermediates [1] Group 2 - Zhonghang Fund has a significant holding in Hecion Pharmaceutical, with its fund "Zhonghang Youxuan Lihang Mixed Initiation A" (022852) holding 203,800 shares, representing 3.25% of the fund's net value [2] - The fund has reported a floating loss of approximately 554,300 yuan as of the latest data [2] - The fund has achieved a return of 100.33% year-to-date, ranking 74 out of 8,172 in its category [2] Group 3 - The fund manager of "Zhonghang Youxuan Lihang Mixed Initiation A" is Wang Sen, who has been in the position for 1 year and 363 days [3] - Under Wang Sen's management, the fund's total asset size is 1.56 billion yuan, with the best return during his tenure being 172.49% and the worst being 13.4% [3]